MultiCell Technologies Inc (MCET)

[TPX]

Multicell Technologies, Inc: La Jolla Cove Investors Inc Makes Purchase

February 15, 2018 - By Winifred Garcia

Multicell Technologies, Inc: La Jolla Cove Investors Inc Makes Purchase

The New La Jolla Cove Investors Inc Holding in Multicell Technologies, Inc
La Jolla Cove Investors Inc reported SC 13G form with the SEC for Multicell Technologies, Inc. Access it here: 000114420418008820. As reported by La Jolla Cove Investors Inc, the filler owns 9.99% or 499,594,775 shares of the -company.



Multicell Technologies, Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows La Jolla Cove Investors Inc’s positive view for Multicell Technologies, Inc.

Business Profile
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The Company and its subsidiaries are developing therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer and interventional cardiology, and peripheral vessel applications. The Company’s portfolio of lead drug candidates is in various stages of discovery optimization, and preclinical and clinical development, and includes MCT-125, MCT-465, MCT-475 and MCT-485. MCT-125 is a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue. MCT-465 is a preclinical synthetic double-stranded ribonucleic acid (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers. MCT-475 is a discovery-stage antibody therapeutic candidate used in combination with dsRNA for the treatment of solid tumor cancers. MCT-485 is a discovery-stage dsRNA therapeutic candidate for the treatment of certain cancers.

SEC Form 13G.

It closed at $0.0001 lastly. It is up 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.

MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. The company has market cap of $500,094. The Company’s product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. It currently has negative earnings. The firm also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications.

More important recent MultiCell Technologies, Inc. (OTCMKTS:MCET) news were published by: Prnewswire.com which released: “Xenogenics Corporation Retains the Emmes Group to Advise on Fund Raising Efforts” on February 23, 2011, also Businesswire.com published article titled: “Hepatocellular Carcinoma – Pipeline Review, H2 2016 – Research and Markets”, Businesswire.com published: “Genisphere Closes $2 Million to Accelerate Development of Targeted Drug …” on September 16, 2014. More interesting news about MultiCell Technologies, Inc. (OTCMKTS:MCET) was released by: Prnewswire.com and their article: “MultiCell Immunotherapeutics And Oxis Biotech Sign Antibody-Drug Conjugate R&D …” with publication date: March 12, 2015.

https://bzweekly.com/2018/02/15/multicell-technologies-inc-la-jolla-cove-investors-inc-makes-purchase/